Kenneth M. Murphy, MD, PhD

Eugene Opie First Centennial Professor
Pathology and Immunology

Immunology Program
Developmental, Regenerative and Stem Cell Biology Program
Molecular Cell Biology Program

  • 314-362-2009

  • 314-362-2004

  • 314-747-4888

  • Box 8118

  • 7766 Clinical Sciences Research Building

  • kmurphy@wustl.edu<'b>

  • https://sites.wustl.edu/murphylab/

  • Dendritic cell and T cell differentiation, gene expression, transcription, inflammation

  • Dendritic cell development and diversification

Research Abstract:

My laboratory examines how specialized lineages of the immune system develop to anticipate various types of infections and to generate the correct quality of immune response. Our initial focus examined the basis of CD4 T cell development into the function helper subsets, such as TH1, TH2, TH17, and so on. Our work defined the physiological basis of instructive differentiation that occurs in response to pathogens and defined the signaling pathways and transcriptional circuits involved. Our early discovery that dendritic cells and macrophages determined the direction of T cell differentiation, by their production of cytokines such as IL-12, led us to examine how myeloid cells evolved to be the decision makers for T cell differentiation in immunity. We are currently focused on defining the developmental basis for dendritic cell diversification into the functional subsets that control induction of the various types of lymphocyte effector responses. This work has practical implications for improved immunotherapy, including vaccine design. Ongoing projects can be found by reading our recently published work and review articles.

Mentorship and Commitment to Diversity Statement:
In our lab, we are committed to creating a supportive and inclusive environment for all members. We believe that diversity and equity are essential for driving innovation and excellence in research, and we are dedicated to promoting and supporting the growth and development of all members of our community, regardless of their background or identity. As such, we actively seek out and value diverse perspectives, and we prioritize the mentorship and professional development of all members of our team. We are committed to creating a lab culture that is welcoming, respectful, and inclusive for all.

Selected Publications:

For a complete list of our publications, see

https://profiles.wustl.edu/en/persons/kenneth-murphy/publications/


Below is a selected list of our recent papers



Liu, T.-T., S. Kim, P. Desai, D.-H. Kim, X. Huang, S. T. Ferris, R. Wu, F. Ou, T. Egawa, S. J. Van Dyken, M. S. Diamond, P. F. Johnson, M. Kubo, T. L. Murphy, and K. M. Murphy. 2022. Ablation of cDC2 development by triple mutations within the Zeb2 enhancer. Nature 607: 142–148.


Ferris, S. T., R. A. Ohara, F. Ou, R. Wu, X. Huang, S. Kim, J. Chen, T.-T. Liu, R. D. Schreiber, T. L. Murphy, and K. M. Murphy. 2022. cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1. Cancer Immunol Res 10: 920–931.


Wu, R., and K. M. Murphy. 2022. DCs at the center of help: Origins and evolution of the three-cell-type hypothesis. J. Exp. Med. 219.


Liu, T.-T., S. Kim, P. Desai, D.-H. Kim, X. Huang, S. T. Ferris, R. Wu, F. Ou, T. Egawa, S. J. Van Dyken, M. S. Diamond, P. F. Johnson, M. Kubo, T. L. Murphy, and K. M. Murphy. 2022. Ablation of cDC2 development by triple mutations within the Zeb2 enhancer. Nature 607: 142–148.


Anderson, D. A., F. Ou, S. Kim, T. L. Murphy, and K. M. Murphy. 2022. Transition from cMyc to L-Myc during dendritic cell development coordinated by rising levels of IRF8. J. Exp. Med. 219.


Murphy, T. L., and K. M. Murphy. 2022. Dendritic cells in cancer immunology. Cell. Mol. Immunol. 19: 3–13.


Huang, X., S. T. Ferris, S. Kim, M. N. K. Choudhary, J. A. Belk, C. Fan, Y. Qi, R. Sudan, Y. Xia, P. Desai, J. Chen, N. Ly, Q. Shi, P. Bagadia, T. Liu, M. Guilliams, T. Egawa, M. Colonna, M. S. Diamond, T. L. Murphy, A. T. Satpathy, T. Wang, and K. M. Murphy. 2021. Differential usage of transcriptional repressor Zeb2 enhancers distinguishes adult and embryonic hematopoiesis. Immunity 54: 1417–1432.e7.



Anderson, D. A., 3rd, C.-A. Dutertre, F. Ginhoux, and K. M. Murphy. 2021. Genetic models of human and mouse dendritic cell development and function. Nat. Rev. Immunol. 21: 101–115.


Kim, S., P. Bagadia, D. A. Anderson 3rd, T.-T. Liu, X. Huang, D. J. Theisen, K. W. O’Connor, R. A. Ohara, A. Iwata, T. L. Murphy, and K. M. Murphy. 2020. High Amount of Transcription Factor IRF8 Engages AP1-IRF Composite Elements in Enhancers to Direct Type 1 Conventional Dendritic Cell Identity. Immunity 53: 759–774.e9.


Ferris, S. T., V. Durai, R. Wu, D. J. Theisen, J. P. Ward, M. D. Bern, J. T. Davidson 4th, P. Bagadia, T. Liu, C. G. Briseño, L. Li, W. E. Gillanders, G. F. Wu, W. M. Yokoyama, T. L. Murphy, R. D. Schreiber, and K. M. Murphy. 2020. cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity. Nature 584: 624–629.



Last Updated: 12/20/2022 1:06:40 PM

Back To Top

Follow us: